Document -
European Commission Grants AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorisation for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
MAVIRET is a new 8-week, pan-genotypic treatment for adult hepatitis C patients without cirrhosis and who are new to treatment
-
License:
All rights reserved
The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
- File format: .pdf